Seom guidelines for the treatment of gastric cancer 2015

被引：0
作者：
M. Martin-Richard
A. Custodio
C. García-Girón
C. Grávalos
C. Gomez
P. Jimenez-Fonseca
J. L. Manzano
C. Pericay
F. Rivera
A. Carrato
机构：
[1] Hospital de la Santa Creu I Sant Pau,Medical Oncology Department
[2] Hospital Universitario Clínico San Carlos,Medical Oncology Department
[3] Hospital Universitario de Burgos,Medical Oncology Department
[4] Hospital Universitario 12 de Octubre,Medical Oncology Department
[5] Hospital Universitario Central de Asturias (HUCA),Medical Oncology Department
[6] Hospital Universitari Germans Trias I Pujol de Badalona,Medical Oncology Department
[7] Hospital de Sabadell-Consorcio Sanitario Parc Taulì,Medical Oncology Department
[8] Hospital Universitario Marqués de Valdecilla,Medical Oncology Department
[9] Hospital Universitario Ramón y Cajal,Medical Oncology Department
来源：
Clinical and Translational Oncology | 2015年 / 17卷
关键词：
Gastric adenocarcinoma; Cardia; Diagnosis; Treatment; Clinical guidelines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Gastric cancer is the fourth cause of death by cancer in Spain and a significant medical problem. Molecular biology results evidence that gastroesophageal junction tumors and gastric cancer should be considered as two independent entities with a different prognosis and treatment approach. Endoscopic resection in very early tumors is feasible. Neoadjuvant and adjuvant therapy in locally advanced resectable tumor increase overall survival and should be considered standard treatments. In stage IV tumors, platinum–fluoropyrimidine-based schedule, with trastuzumab in HER2-overexpressed tumors, is the first-line treatment. Different therapies in second line have demonstrated in randomized studies their clear benefit in survival improvement.
引用
收藏
页码：996 / 1004
页数：8
相关论文
共 286 条
  • [1] Crew KD(2004)Epidemiology of upper gastrointestinal malignancies Semin Oncol 31 450-464
  • [2] Neugut AI(2014)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Cancer incidence and Mortality Worldwire: IARC 136 E359-E386
  • [3] Ferlay J(2015)Classification of adenocarcinoma of the oesophagogastric junction Int J Cancer 85 1457-1459
  • [4] Soerjomataram I(1998)Molecular classification of gastric cancer: a new paradigm Br J Surg 17 2693-2701
  • [5] Dikshit R(2011)Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil Clin Cancer Res 145 554-565
  • [6] Eser S(2013)A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets Gastroenterology 61 673-684
  • [7] Mathers C(2012)Comprehensive molecular characterization of gastric adenocarcinoma Gut 513 202-209
  • [8] Rebelo M(2014)Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Nature 21 449-456
  • [9] Ferlay J(2015)Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils Nat Med 18 1484-1491
  • [10] Soerjomataram I(2011)Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer Ann Surg Oncol 105 400-404
12345678910